Research programme: nerve-targeted gene therapy - Periphagen

Drug Profile

Research programme: nerve-targeted gene therapy - Periphagen

Alternative Names: NC 3; NE 2; NE2 Endomorphin; NG 2; NG2 GAD; NN1 Neurotrophin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical; Periphagen Holdings; University of Michigan
  • Class Gene therapies
  • Mechanism of Action GABA modulators; Glutamate decarboxylase stimulants; Nerve growth factor stimulants; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Erectile dysfunction; Glioma; Neuropathic pain; Peripheral nervous system diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Intradermal, Injection)
  • 04 Nov 2017 No recent reports of development identified for research development in Peripheral-nervous-system-diseases(Prevention, Chemotherapy-induced) in USA (Parenteral, Injection)
  • 12 Oct 2012 Preclinical development is ongoing for Neuropathic pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top